vs
ExlService Holdings, Inc.（EXLS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是ExlService Holdings, Inc.的1.1倍（$622.0M vs $542.6M），Royalty Pharma plc净利率更高（34.4% vs 11.1%，领先23.3%），ExlService Holdings, Inc.同比增速更快（12.7% vs 4.8%），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 4.6%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
EXLS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.1倍
$542.6M
营收增速更快
EXLS
高出7.9%
4.8%
净利率更高
RPRX
高出23.3%
11.1%
两年增速更快
EXLS
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $622.0M |
| 净利润 | $60.2M | $214.2M |
| 毛利率 | 38.6% | — |
| 营业利润率 | 14.4% | 62.4% |
| 净利率 | 11.1% | 34.4% |
| 营收同比 | 12.7% | 4.8% |
| 净利润同比 | 18.9% | 2.9% |
| 每股收益（稀释后） | $0.38 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSRPRX
| Q4 25 | $542.6M | $622.0M | ||
| Q3 25 | $529.6M | $609.3M | ||
| Q2 25 | $514.5M | $578.7M | ||
| Q1 25 | $501.0M | $568.2M | ||
| Q4 24 | $481.4M | $593.6M | ||
| Q3 24 | $472.1M | $564.7M | ||
| Q2 24 | $448.4M | $537.3M | ||
| Q1 24 | $436.5M | $568.0M |
净利润EXLSRPRX
| Q4 25 | $60.2M | $214.2M | ||
| Q3 25 | $58.2M | $288.2M | ||
| Q2 25 | $66.1M | $30.2M | ||
| Q1 25 | $66.6M | $238.3M | ||
| Q4 24 | $50.7M | $208.2M | ||
| Q3 24 | $53.0M | $544.0M | ||
| Q2 24 | $45.8M | $102.0M | ||
| Q1 24 | $48.8M | $4.8M |
毛利率EXLSRPRX
| Q4 25 | 38.6% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 37.7% | — | ||
| Q1 25 | 38.6% | — | ||
| Q4 24 | 38.1% | — | ||
| Q3 24 | 37.8% | — | ||
| Q2 24 | 37.1% | — | ||
| Q1 24 | 37.4% | — |
营业利润率EXLSRPRX
| Q4 25 | 14.4% | 62.4% | ||
| Q3 25 | 14.4% | 70.1% | ||
| Q2 25 | 15.8% | 36.3% | ||
| Q1 25 | 15.7% | 94.0% | ||
| Q4 24 | 14.8% | 60.9% | ||
| Q3 24 | 14.7% | — | ||
| Q2 24 | 13.7% | 50.2% | ||
| Q1 24 | 14.1% | -13.0% |
净利率EXLSRPRX
| Q4 25 | 11.1% | 34.4% | ||
| Q3 25 | 11.0% | 47.3% | ||
| Q2 25 | 12.8% | 5.2% | ||
| Q1 25 | 13.3% | 41.9% | ||
| Q4 24 | 10.5% | 35.1% | ||
| Q3 24 | 11.2% | 96.3% | ||
| Q2 24 | 10.2% | 19.0% | ||
| Q1 24 | 11.2% | 0.8% |
每股收益（稀释后）EXLSRPRX
| Q4 25 | $0.38 | $0.49 | ||
| Q3 25 | $0.36 | $0.67 | ||
| Q2 25 | $0.40 | $0.07 | ||
| Q1 25 | $0.40 | $0.55 | ||
| Q4 24 | $0.31 | $0.46 | ||
| Q3 24 | $0.33 | $1.21 | ||
| Q2 24 | $0.28 | $0.23 | ||
| Q1 24 | $0.29 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $618.7M |
| 总债务越低越好 | $298.6M | $9.0B |
| 股东权益账面价值 | $912.7M | $9.7B |
| 总资产 | $1.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资EXLSRPRX
| Q4 25 | $328.4M | $618.7M | ||
| Q3 25 | $390.1M | $938.9M | ||
| Q2 25 | $353.3M | $631.9M | ||
| Q1 25 | $331.4M | $1.1B | ||
| Q4 24 | $340.6M | $929.0M | ||
| Q3 24 | $325.8M | $950.1M | ||
| Q2 24 | $276.1M | $1.8B | ||
| Q1 24 | $246.2M | $843.0M |
总债务EXLSRPRX
| Q4 25 | $298.6M | $9.0B | ||
| Q3 25 | $354.8M | $8.9B | ||
| Q2 25 | $260.0M | $8.0B | ||
| Q1 25 | $307.3M | $7.6B | ||
| Q4 24 | $288.5M | $7.6B | ||
| Q3 24 | $344.7M | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益EXLSRPRX
| Q4 25 | $912.7M | $9.7B | ||
| Q3 25 | $952.4M | $9.6B | ||
| Q2 25 | $1.1B | $9.5B | ||
| Q1 25 | $1.0B | $9.8B | ||
| Q4 24 | $929.9M | $10.3B | ||
| Q3 24 | $907.6M | $10.3B | ||
| Q2 24 | $852.6M | $9.8B | ||
| Q1 24 | $803.3M | $9.9B |
总资产EXLSRPRX
| Q4 25 | $1.7B | $19.6B | ||
| Q3 25 | $1.7B | $19.3B | ||
| Q2 25 | $1.7B | $18.3B | ||
| Q1 25 | $1.7B | $17.6B | ||
| Q4 24 | $1.6B | $18.2B | ||
| Q3 24 | $1.6B | $18.0B | ||
| Q2 24 | $1.5B | $17.7B | ||
| Q1 24 | $1.4B | $16.1B |
负债/权益比EXLSRPRX
| Q4 25 | 0.33× | 0.92× | ||
| Q3 25 | 0.37× | 0.93× | ||
| Q2 25 | 0.25× | 0.84× | ||
| Q1 25 | 0.30× | 0.78× | ||
| Q4 24 | 0.31× | 0.74× | ||
| Q3 24 | 0.38× | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | — |
| 自由现金流率自由现金流/营收 | 19.6% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 1.95× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $298.1M | — |
8季度趋势，按日历期对齐
经营现金流EXLSRPRX
| Q4 25 | $117.4M | $827.1M | ||
| Q3 25 | $120.7M | $702.6M | ||
| Q2 25 | $109.4M | $364.0M | ||
| Q1 25 | $3.2M | $596.1M | ||
| Q4 24 | $105.3M | $742.5M | ||
| Q3 24 | $110.1M | $703.6M | ||
| Q2 24 | $74.9M | $658.2M | ||
| Q1 24 | $-21.9M | $664.6M |
自由现金流EXLSRPRX
| Q4 25 | $106.5M | — | ||
| Q3 25 | $106.4M | — | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $-9.7M | — | ||
| Q4 24 | $95.3M | — | ||
| Q3 24 | $97.3M | — | ||
| Q2 24 | $62.8M | — | ||
| Q1 24 | $-33.1M | — |
自由现金流率EXLSRPRX
| Q4 25 | 19.6% | — | ||
| Q3 25 | 20.1% | — | ||
| Q2 25 | 18.5% | — | ||
| Q1 25 | -1.9% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.6% | — | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | -7.6% | — |
资本支出强度EXLSRPRX
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.6% | — |
现金转化率EXLSRPRX
| Q4 25 | 1.95× | 3.86× | ||
| Q3 25 | 2.08× | 2.44× | ||
| Q2 25 | 1.66× | 12.06× | ||
| Q1 25 | 0.05× | 2.50× | ||
| Q4 24 | 2.08× | 3.57× | ||
| Q3 24 | 2.08× | 1.29× | ||
| Q2 24 | 1.63× | 6.45× | ||
| Q1 24 | -0.45× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
